Project Grant R43GM164214
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $312K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Andover, MA 01810, USA
Similar Awards
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $273,652 to Phage Refinery LLC aims to develop a rapid and efficient parametric model for predicting the likelihood that a given bacteriophage (phage) will survive sufficiently long in the presence of an active immune system to be effective as a treatment against their target bacterial infection. The project will gather physical parameters and in-vivo persistence data for 400...
- The National Institute of General Medical Sciences awarded Photothermal Spectroscopy Corp. $306,802 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop a next-generation photothermal stimulated Raman scattering (PT-SRS) microscope for high-speed, label-free chemical imaging of live cells in standard multiwell culture plates. Current PT-SRS implementations use transmission geometries that prevent compatibility with inverted microscopes and...
- Cobio Diagnostics Inc. received a $256,000 Project Grant award from the National Science Foundation on April 1, 2021 to support work concluding on March 31, 2022. The grant was awarded under the NSF's Engineering program (CFDA 47.041), which aims to improve quality of life and economic strength through engineering research and education. Specifically, the grant funds Cobio Diagnostics' "SBIR PHASE I: PHAGE-AMPLIFIED IDENTIFICATION AND ANTIMICROBIAL SUSCEPTIBILITY TEST" project. This...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award of $984,381 to Cobio Diagnostics Inc. in Aurora, Colorado aims to expand a diagnostic tool that enables rapid, direct-from-specimen identification and antimicrobial susceptibility testing of major bloodborne bacterial pathogens. The project will develop a regulatory pathway for FDA clearance, characterize antibodies to expand the test, and validate the expanded tests...
- The National Institute of General Medical Sciences awarded Midwest Bioprocessing Center, Inc. $313,770 on September 1, 2026, under the SBIR program to develop a scalable fermentation system for producing pseudaminic acids and their CMP-activated derivatives. The award supports Phase I research to establish proof-of-concept for cost-effective biosynthetic production of pseudaminic acid compounds—specifically PSE5AC7AC and analogs PSE5AC7HB and PSE5AC7FM in free and CMP-activated forms....
- This $228,697 National Science Foundation award under the Engineering program (CFDA 47.041) will support the development of an optical biosensor technology to facilitate drug screening and validation efforts. Auctus Biologics, Inc. will utilize a proprietary temperature, pH, and chemically stable protein composed of two fragments that bind with antibody-like affinity and specificity. Over the one-year period ending January 2023, the company will establish the technology's suitability for...
- The National Institute of General Medical Sciences awarded Potomac Affinity Proteins, LLC $377,602 on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859, Assistance Listing R43GM159468) to develop protease chain reaction (PROCR) technology for rapid, highly sensitive, and quantitative detection of biomolecules in mix-and-read assays. The recipient will engineer protease and inhibitor components to optimize catalytic turnover and detect three target...
- Felix Biotechnology Inc. received a $256,000 Small Business Innovation Research Phase I Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program. The 12-month project aims to leverage machine learning techniques to enable generalized phage therapy for pulmonary infections. Phage therapy utilizes bacteriophages, or viruses that infect bacteria, as an alternative to traditional antibiotics. This award will support Felix Biotechnology's...
- Vulcan Biologics Inc. received a $989,854 cooperative agreement award from the National Science Foundation Division of Industrial Innovation under the Engineering federal grant program (CFDA 47.041) to support the development of a bacteriophage-based microbial gene therapy platform for in situ engineering of microbiomes. This project will leverage bacteriophages to deliver targeted genetic modifications within complex microbial communities, with the goal of engineering the function and...
- The National Institute of General Medical Sciences awarded Georgia State University Research Foundation Inc. $434,729 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research on bacteriophage gene essentiality and infection dynamics across environmental contexts. The award funds research to map phage gene function and track infection dynamics using complementary molecular approaches. The work will exploit DNA mismatch-repair deficient...